Kevin Hollevoet
- Biotechnology top 5%
-
- Occupational and environmental lung diseases 10
- Pleural and Pulmonary Diseases 5
-
- Toxin Mechanisms and Immunotoxins 5
-
- CAR-T cell therapy research 4
-
- Monoclonal and Polyclonal Antibodies Research 6
-
- Virus-based gene therapy research 6
-
- Viral Infectious Diseases and Gene Expression in Insects 6
-
- Bacteriophages and microbial interactions 3
- Co-authors
- Paul DeclerckIra PastanJan P. van MeerbeeckKristiaan NackaertsGerhard NiederfellnerJoris DelangheLionel BosquéePaul Germonpré
- Journals
- Journal of Clinical Oncology (2 papers)PLoS ONE (1 paper)American Journal of Respiratory and Critical Care Medicine (1 paper)
- Partner nations
- BelgiumUnited StatesJapan
In The Last Decade
Kevin Hollevoet
30 papers receiving 829 citations
Peers
Comparison fields: 5 of 51
- Biotechnology 173
- Pulmonary and Respiratory Medicine 493
- Immunology 208
- Oncology 168
- Radiology, Nuclear Medicine and Imaging 120
Countries citing papers authored by Kevin Hollevoet
This map shows the geographic impact of Kevin Hollevoet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kevin Hollevoet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kevin Hollevoet more than expected).
Fields of papers citing papers by Kevin Hollevoet
This network shows the impact of papers produced by Kevin Hollevoet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kevin Hollevoet. The network helps show where Kevin Hollevoet may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Kevin Hollevoet, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 2 | |
| 2 | 2021 | 10 | |
| 3 | 2021 | 12 | |
| 4 | 2020 | 17 | |
| 5 | 2020 | 8 | |
| 6 | 2020 | 7 | |
| 7 | 2017 | 48 | |
| 8 | 2015 | 10 | |
| 9 | 2015 | 23 | |
| 10 | 2014 | 93 | |
| 11 | 2014 | 137 | |
| 12 | 2013 | 15 | |
| 13 | 2012 | 3 | |
| 14 | 2011 | 26 | |
| 15 | 2011 | 17 | |
| 16 | 2011 | 66 | |
| 17 | 2011 | 41 | |
| 18 | 2010 | 78 | |
| 19 | Validation of soluble mesothelin: design and preliminary results of a Belgian multicentric observational study | 2009 | 1 |
| 20 | Glomerular filtration rate is a confounder for determination of serum soluble mesothelin | 2009 | 3 |
About Kevin Hollevoet
Kevin Hollevoet is a scholar working on Biotechnology, Pulmonary and Respiratory Medicine and Immunology, having authored 30 papers that have together received 850 indexed citations. Recurring topics across this work include Occupational and environmental lung diseases (10 papers), Virus-based gene therapy research (6 papers), Viral Infectious Diseases and Gene Expression in Insects (6 papers), Monoclonal and Polyclonal Antibodies Research (6 papers), Pleural and Pulmonary Diseases (5 papers), Toxin Mechanisms and Immunotoxins (5 papers), CAR-T cell therapy research (4 papers) and Bacteriophages and microbial interactions (3 papers). The work is most often cited by research in Biotechnology (173 citations), Pulmonary and Respiratory Medicine (493 citations) and Immunology (208 citations). Kevin Hollevoet has collaborated with scholars based in Belgium, United States and Japan. Frequent co-authors include Paul Declerck, Ira Pastan, Jan P. van Meerbeeck, Kristiaan Nackaerts, Gerhard Niederfellner, Joris Delanghe, Lionel Bosquée, Paul Germonpré, Paul De Vuyst and Yoshiro Kishi. Their work appears in journals such as Journal of Clinical Oncology, PLoS ONE and American Journal of Respiratory and Critical Care Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.